AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32822287
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib (LAP) plus Trastuzumab (TRAS) plus Aromatase Inhibitor (AI)
Trial: 32822287
Drug: Trastuzumab (TRAS)
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab (TRAS) plus Aromatase Inhibitor (AI)
Trial: 32822287
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib (LAP) plus Aromatase Inhibitor (AI)
Trial: 34348226
Drug: High-Intensity Interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Interval Training (delivered twice weekly for 8 weeks)
Trial: 33492872
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow nasal oxygen (50 l min-1 and a 50:50 oxygen to air ratio)
Trial: 33492872
Drug: Facemask oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facemask oxygen (≥ 8 l min-1)
Trial: 32310854
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin therapy only
Trial: 32310854
Drug: Oral vildagliptin
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Oral vildagliptin plus subcutaneous insulin
Trial: 33588077
Drug: Videoconference-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videoconference-delivered cognitive behaviour therapy for insomnia (CBT-I)
Trial: 33460256
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (SBP < 120 mm Hg)
Trial: 33460256
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment (SBP < 140 mm Hg)
Trial: 32009299
Drug: Topical TFB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TFB application
Trial: 32084526
Drug: Liver-directed concurrent
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver-directed concurrent chemoradiotherapy (LD-CCRT) and sequential sorafenib treatment (400 mg, twice daily)
Trial: 35289183
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (200 mg/kg) administered intravenously for 30 minutes after return of spontaneous circulation
Trial: 34266522
Drug: Lactase treatment
RxNorm normalized name: Lactase
DrugBank: Tilactase (DB13761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactase treatment (4 drops of lactase additive, 180 mg added into preterm formula or breast milk)
Trial: 34266522
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo, oral probiotics at half an hour after feeding, and abdominal massage)
Trial: 34366180
Drug: Digital media-based
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital media-based hand therapy (self-directed, 12-week protocol)
Trial: 34366180
Drug: Traditional hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional hand therapy (12-week protocol)
Trial: 34828790
Drug: Combined Music
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Music Therapy (MT) and Skin-to-Skin Care (SSC)
Trial: 33839489
Drug: Nasal betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal betamethasone drops (3 times daily for a maximum of one month)
Trial: 33839489
Drug: Placebo (9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (9% NaCl drops, similar dosage to betamethasone)
Trial: 32911009
Drug: SDA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDA treatment using resin bonded bridgework (RBB)
Trial: 35723714
Drug: Adjunctive botanical
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive botanical patch applications (3 times on day 0 and once daily on days 1-6)
Trial: 35723714
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (SRP alone, control)
Trial: 35723714
Drug: Adjunctive botanical
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive botanical patch applications
Trial: 36053757
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg MTX subcutaneously
Trial: 36053757
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg MTX orally
Trial: 36053757
Drug: MJK101 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MJK101 (subcutaneous MTX)
Trial: 36030801
Drug: Midwife group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midwife group (sublingual misoprostol 400 μg every 3 hours for up to five doses)
Trial: 36030801
Drug: Physician group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician group (sublingual misoprostol 400 μg every 3 hours for up to five doses)
Trial: 36345347
Drug: Intravenous sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sildenafil dosed every 8 hours for up to 34 days at doses of 0.125, 0.5, and 1 mg/kg/dose in cohorts 1, 2, and 3, respectively.
Trial: 36345347
Drug: Enteral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral sildenafil dosed every 8 hours for up to 34 days at doses double the IV doses.
Trial: 35815354
Drug: BFF MDI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BFF MDI (budesonide/formoterol fumarate dihydrate metered dose inhaler) 320/10 µg with a spacer
Trial: 35815354
Drug: BUD/FORM DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FORM DPI (budesonide/formoterol fumarate dry powder inhaler) 320/9 µg
Trial: 33778945
Drug: 36 or
RxNorm normalized name: pediatric multivitamin no.136 ORAL TABLET,CHEWABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 or 54 mg of extended-release methylphenidate
Trial: 33933265
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet gel application in tubularized incised plate (TIP) repair
Trial: 33933265
Drug: TIP repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIP repair without autologous platelet gel
Trial: 35830848
Drug: Cinnamon infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon infusion (2 g, Cinnamomum sp.)
Trial: 32212012
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin at a prophylactic dose (SHPD) - enoxaparin 4000 U/day
Trial: 32212012
Drug: SHPD reduction/discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHPD reduction/discontinuation
Trial: 34312872
Drug: Early orthodontic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early orthodontic therapy (OT) at 4 weeks post surgery
Trial: 34312872
Drug: Late orthodontic
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late orthodontic therapy (OT) at 6 months post surgery
Trial: 34312872
Drug: Early orthodontic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early orthodontic therapy (OT)
Trial: 34312872
Drug: Late orthodontic
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late orthodontic therapy (OT)
Trial: 35192411
Drug: Selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75 mg orally twice daily for approximately 5 weeks
Trial: 33522954
Drug: Healthy low-carbohydrate
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy low-carbohydrate diet (< 40 g of net carbohydrates for the first 3 months and < 40 to 60 net grams for months 3 to 6)
Trial: 35575839
Drug: 8-week distance-delivered
RxNorm normalized name: CISTANCHE TINCTORIA STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week distance-delivered social skills program, sessions offered twice a week for 90 min
Trial: 33150640
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT‐E)
Trial: 35688173
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg IV every 2 weeks) plus Cabozantinib (40 mg orally once daily)
Trial: 35688173
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg orally once daily)
Trial: 34331676
Drug: Probiotics used
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics used concurrently with antibiotics (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis) for 1 week
Trial: 34331676
Drug: Probiotics used
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics used after antibiotics for 1 week
Trial: 34331676
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (piperacillin–tazobactam) for 1 week
Trial: 34331676
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention (antibiotic therapy only)
Trial: 32727497
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (weekly cisplatin with IMRT)
Trial: 35086790
Drug: OligoG (1050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OligoG (1050 mg daily)
Trial: 32723265
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and an oral integrator (Micronil Dol®) composed of acetyl‐L‐carnitine, α‐lipoic acid, quercetin, bromelain, pantothenic acid, C and B1 and B2 and B6 and B12 vitamins
Trial: 34424730
Drug: Weekly rifapentine‐isoniazid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly rifapentine‐isoniazid for 3 months (n=3610)
Trial: 34424730
Drug: Daily isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily isoniazid for 6 months (n=404)
Trial: 32773581
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of aspirin daily during pregnancy
Trial: 32773581
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily during pregnancy
Trial: 39300222
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg/day
Trial: 32326796
Drug: Ticagrelor (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (aspirin plus ticagrelor)
Trial: 32326796
Drug: Clopidogrel (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (aspirin plus clopidogrel)
Trial: 34259404
Drug: Auricular intradermal
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular intradermal needling
Trial: 35671038
Drug: Tralokinumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab (300 mg) administered subcutaneously every 2 weeks
Trial: 38631826
Drug: Aspirin 150
RxNorm normalized name: aspirin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 150 mg daily
Trial: 35958552
Drug: Low-dose rituximab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rituximab (600 mg)
Trial: 34174084
Drug: Flexible and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible and pragmatic approaches (e.g., interviews instead of focus groups)
Trial: 34916086
Drug: Apalutamide 240
RxNorm normalized name: apalutamide 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide 240 mg/d
Trial: 34654929
Drug: Drug arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug arm
Trial: 35500786
Drug: High dose-rate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose-rate brachytherapy (HDR) monotherapy
Trial: 35500786
Drug: High dose-rate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose-rate brachytherapy (HDR) boost
Trial: 35469481
Drug: Mepivacaine injection
RxNorm normalized name: mepivacaine Injection
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mepivacaine injection into the temporalis tendon
Trial: 35469481
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor injection into the temporalis tendon
Trial: 35469481
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor injection
Trial: 32155399
Drug: Inadequate adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inadequate adjuvant treatment
Trial: 33631357
Drug: Ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 mg orally daily for 14 days
Trial: 32363556
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (10,000 IU twice weekly) combined with clomiphene citrate (50 mg twice daily for 5 days)
Trial: 32363556
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with calcium (1250 mg twice daily) combined with clomiphene citrate (50 mg twice daily for 5 days)
Trial: 34062587
Drug: Betalactam-antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betalactam-antibiotics
Trial: 34062587
Drug: Post-treatment patients
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment patients
Trial: 34468794
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 mg twice daily)
Trial: 33407490
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose walnut (30 g/d)
Trial: 33407490
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose walnut (60 g/d)
Trial: 33407490
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (low dose, high dose, control)
Trial: 32192623
Drug: Bupropion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion therapy along with standard counselling
Trial: 34714969
Drug: Abelacimab (30-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abelacimab (30-150 mg) intravenous single doses
Trial: 34714969
Drug: Abelacimab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abelacimab (120 mg and 180 mg) subcutaneous monthly doses
Trial: 34714969
Drug: Abelacimab (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abelacimab (intravenous and subcutaneous)
Trial: 36432401
Drug: Dietary prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary prescription with nutritional recommendations, nutritional education program based on playful strategies, suggestions of typical and accessible Brazilian foods and intensive monitoring
Trial: 32945627
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (daily dosage not specified) for 6 months
Trial: 32710585
Drug: Herbal cream
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal cream (cream A) applied topically twice-daily
Trial: 32710585
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream (cream B) applied topically twice-daily
Trial: 33879077
Drug: Eculizumab (resumed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (resumed recommended dose after trial of weaning)
Trial: 33879077
Drug: Eculizumab (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (initial treatment)
Trial: 33436973
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) use
Trial: 34259400
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (tapping at acupoints along meridian + thunder-fire moxibustion)
Trial: 34259400
Drug: Routine group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine group (routine treatment and nursing)
Trial: 33469679
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of OVV-Beclin1 and R-CHOP
Trial: 38168442
Drug: 5% 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-Fluorouracil (5-FU) cream
Trial: 33858561
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide (ATO) combined with chemotherapy
Trial: 36177741
Drug: metronidazole gel
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metronidazole gel (0.75%)
Trial: 34218516
Drug: Guided Biofilm
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided Biofilm Therapy (GBT) using erythritol powder (AIRFLOW®)
Trial: 35197363
Drug: JAK inhibitors
RxNorm normalized name: Janus-associated kinase (JAK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JAK inhibitors
Trial: 32994251
Drug: 0.145% fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.145% fluoride gel applied using custom trays after brushing every night while sleeping
Trial: 32994251
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instructions as usual
Trial: 33650454
Drug: Euglycemic no-insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Euglycemic no-insulin cohort (ENo-I, n = 111)
Trial: 35330828
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg in 10 min) followed by a constant infusion rate (0.5 μg kg−1 h−1) (D2 group)
Trial: 35330828
Drug: Dexmedetomidine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine at a constant infusion rate (0.5 μg kg−1 h−1) (D1 group)
Trial: 35330828
Drug: Propofol- and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol- and remifentanil-based total intravenous anesthesia (T group)
Trial: 36416665
Drug: Automated Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated Oxygen Administration (AOA)
Trial: 33331859
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg and 2.0 mg, administered monthly or on an as-needed basis over 24 months
Trial: 32237012
Drug: High-dose spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose spironolactone (100 mg daily)
Trial: 35637354
Drug: Neck stretching
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck stretching and movement exercises three times daily for four weeks post-surgery
Trial: 33279389
Drug: High-dose dabigatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dabigatran (150 mg bid), rivaroxaban, high-dose edoxaban (60 mg daily)
Trial: 33279389
Drug: Antiplatelet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet treatment with aspirin and P2Y12 receptor antagonists
Trial: 33279389
Drug: DOACs (Direct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOACs (Direct Oral Anticoagulants)
Trial: 35137572
Drug: Treatment satisfaction
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment satisfaction questionnaire
Trial: 35112931
Drug: BH4 (≈10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BH4 (≈10 mg/kg, post)